Quantcast

Why Johnson & Johnson Stock Has Lost 13% So Far in 2018


What happened

Shares of healthcare titan Johnson & Johnson (NYSE: JNJ) trailed the market through the first six months of 2018 by shedding 13%, compared to a 2% uptick in the S&P 500 , according to data provided by S&P Global Market Intelligence .

^SPX Chart

^SPX data by YCharts .

The decline has pushed the stock below broader market returns over the past one-year and three-year time frames.

So what

Johnson & Johnson's latest results haven't given investors much to worry about. In fact, sales and profits beat expectations in the most recent quarter, thanks mainly to a booming pharmaceutical segment. The drugmaker's portfolio continues to grow , which is helping offset some of the pain from declining prices for its blockbuster Remicade treatment.

Two laboratory researchers at work

Image source: Getty Images.

Now what

CEO Alex Gorsky and his team raised their sales outlook in April, and now believe organic growth should range between 4% and 5%, up from the prior target of between 3.5% and 4.5%. Over the short term, investors are concerned that a political battle over drug pricing might harm Johnson & Johnson's profitability, and so shares are likely to react to major news on that front.

The long-term competitive outlook is bright, though. It's especially so considering that reduced tax expenses are slated to power a 15% increase in research and development spending over the next four years, to $30 billion.

10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of June 4, 2018

Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool owns shares of Johnson & Johnson. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Personal Finance , Stocks
Referenced Symbols: JNJ



More from Motley Fool

Subscribe






Motley Fool
Contributor:

Motley Fool

Market News, Investing










Research Brokers before you trade

Want to trade FX?